A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung

Inclusion Criteria:

Diagnosis of squamous or mixed histology non-small cell lung cancer

Treated with pembrolizumab in combination with platinum-based chemotherapy as initial therapy for advanced or metastatic disease (stage IIIB or IV)

First cycle of pembrolizumab received after 06/01/2018
Permanently discontinued 1L pembrolizumab treatment

Initiated second-line treatment at least 3 months prior to the date of data collection, with either :

Afatinib
Any chemotherapy
Age ≥ 18 years

Exclusion Criteria:

-Received pembrolizumab in combination with platinum-based chemotherapy as part of an interventional clinical trial